Who Owns Haemonetics Company?

Haemonetics Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Haemonetics Corporation?

Understanding the ownership structure of a global medical technology leader like Haemonetics Corporation is key to grasping its strategic direction and market standing. Delving into who owns Haemonetics offers valuable insights into its governance and long-term vision within the dynamic healthcare sector. Founded in 1971 by Dr. Allen (Jack) Latham in Braintree, Massachusetts, the company initially focused on revolutionizing blood processing and handling through advanced medical technologies, later relocating its headquarters to Boston.

Haemonetics has transformed from its origins as a pioneering medical device company specializing in blood collection and processing systems into a worldwide leader in comprehensive blood management solutions. As of July 2025, Haemonetics (NYSE: HAE) commands a market capitalization ranging from approximately $3.48 billion to $3.63 billion USD, underscoring its significant presence in the medical devices industry. Its extensive product range caters to blood and plasma centers, hospitals, and healthcare providers globally, encompassing devices and software for blood and plasma collection, processing, and storage, including innovative solutions like the Haemonetics BCG Matrix.

The Haemonetics ownership structure reveals a significant presence of institutional investors, which collectively hold a substantial portion of the company's stock. These large entities, such as investment management firms and mutual funds, often play a crucial role in shaping corporate strategy through their voting power and active engagement. While specific percentages can fluctuate, institutional ownership typically represents a dominant force in publicly traded companies like Haemonetics, influencing decisions on everything from executive compensation to long-term strategic planning.

When examining Haemonetics company ownership, it's important to consider the various types of shareholders. Publicly traded companies like Haemonetics are owned by their shareholders, and understanding who these shareholders are provides a clearer picture of the company's financial backing and governance. The Haemonetics stock ownership is distributed among a wide array of investors, ranging from large institutional holders to individual retail investors. The Haemonetics major investors are often key players in the financial markets, their investment decisions reflecting confidence in the company's performance and future prospects.

The question of 'Is Haemonetics publicly traded' is answered with a definitive yes, as its shares are listed on the New York Stock Exchange under the ticker symbol HAE. This public trading status means that Haemonetics ownership is accessible to a broad range of investors. Identifying 'Who are the largest shareholders of Haemonetics' requires reviewing regulatory filings, which detail the beneficial owners of the company's stock. These filings are essential for understanding the Haemonetics ownership structure explained, including the percentage of Haemonetics owned by institutions and the influence of company insiders.

For those seeking detailed information on Haemonetics investor relations contact or Haemonetics financial reports ownership details, consulting the company's official investor relations section on its website is the most direct approach. This resource typically provides access to annual reports, quarterly earnings, and proxy statements, which contain comprehensive data on Haemonetics shareholders and the Haemonetics board of directors ownership. The company's profile ownership is continually updated to reflect changes in its shareholder base, offering transparency to the market.

Regarding whether 'Does Haemonetics have a controlling owner,' as a publicly traded entity, control is typically dispersed among its shareholders, with no single individual or entity holding a majority stake that would grant absolute control. The 'Who is the CEO of Haemonetics' is a matter of public record, and the CEO, along with the board of directors, oversees the company's operations and strategic direction, accountable to the broader shareholder base. Understanding 'Who are Haemonetics institutional investors' and 'Who are the beneficial owners of Haemonetics' provides a comprehensive view of the company's ownership landscape.

Haemonetics Corporation's journey began in 1971, founded by Dr. Allen (Jack) Latham, Jr. Dr. Latham, a scientist with experience at Arthur D. Little Company and Harvard Medical School, identified a significant need for advancements in blood processing. His groundbreaking invention, the Latham Bowl, a transparent, disposable centrifuge bowl, was instrumental in automating blood separation through centrifugation. This innovation formed the basis for the company's initial product, the Model 10 blood processing machine, setting the stage for Haemonetics' future in blood management solutions.

While precise details regarding the initial equity distribution among the founding team or early investors are not publicly documented, the company's establishment in Braintree, Massachusetts, was supported by a team possessing expertise in both medical technology and business acumen. The company transitioned to public ownership in 1979.

A significant shift in Haemonetics' ownership occurred in 1983 when it was acquired by American Hospital Supply Corporation (AHS). However, this period of consolidated ownership was relatively brief. Following Baxter Travenol Laboratories, Inc.'s acquisition of AHS in 1985, Haemonetics was divested. This divestiture was a strategic move to address antitrust concerns, which ultimately allowed Haemonetics to regain its independence and concentrate on its core mission of developing blood management solutions. The company subsequently completed another initial public offering (IPO) on May 9, 1991, listing its shares on the New York Stock Exchange (NYSE) under the ticker symbol HAE, making it a publicly traded entity once more.

Founding Vision

Dr. Allen (Jack) Latham, Jr. founded Haemonetics in 1971. His vision was driven by the need for improved blood processing systems.

Key Innovation

The 'Latham Bowl,' a transparent, disposable centrifuge bowl, was Dr. Latham's pivotal invention. It automated blood separation via centrifugation.

Early Public Offering

Haemonetics first became a publicly owned company in 1979. This marked its initial entry into the public markets.

Acquisition and Divestiture

In 1983, American Hospital Supply Corporation acquired Haemonetics. It was later divested in 1985 after Baxter Travenol Laboratories, Inc. acquired AHS.

Return to Independence

The divestiture allowed Haemonetics to regain independence and refocus on its core blood management technologies. This strategic move was crucial for its future growth.

Second IPO

Haemonetics completed its second initial public offering on May 9, 1991. The company began trading on the NYSE under the ticker HAE.

Haemonetics Ownership Evolution

The ownership structure of Haemonetics has evolved significantly since its founding. From its inception as a privately held entity driven by its founder's innovations, it transitioned to public ownership, experienced an acquisition and subsequent divestiture, and ultimately re-established itself as an independent, publicly traded company. This trajectory highlights the dynamic nature of corporate ownership in the medical technology sector and the strategic decisions made to ensure continued focus on its specialized market. Understanding this history is key to grasping the current Haemonetics ownership landscape and its Mission, Vision & Core Values of Haemonetics.

• Founded in 1971 by Dr. Allen (Jack) Latham, Jr.
• Pioneered automated blood separation with the Latham Bowl.
• First became publicly owned in 1979.
• Acquired by American Hospital Supply Corporation in 1983.
• Divested in 1985, regaining independence.
• Completed a second IPO on May 9, 1991, trading as HAE on the NYSE.

Haemonetics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Haemonetics Corporation became a publicly traded company on May 9, 1991, marking a significant shift in its ownership structure. As a company listed on the NYSE, its ownership is now dispersed among various investor groups, including large institutions, individual investors, and company insiders. This transition established a framework where public market dynamics and shareholder interests play a crucial role in the company's governance and strategic decisions.

The evolution of Haemonetics' ownership reflects its growth and integration into the public capital markets. The company's market capitalization, which as of July 2025 is estimated to be between $3.48 billion and $3.63 billion USD, indicates its substantial presence. With 50,841,442 shares of common stock outstanding as of May 15, 2024, the distribution of these shares among different stakeholders defines the Haemonetics ownership structure.

Institutional investors are the dominant force in Haemonetics' ownership, holding a substantial portion of its stock. This widespread institutional backing suggests a strong belief in the company's performance and future prospects. Key institutional shareholders include prominent entities such as BlackRock, Inc., Vanguard Group Inc., Neuberger Berman Group LLC, Wellington Management Group Llp, T. Rowe Price Investment Management, Inc., State Street Corp, and iShares. For instance, Vanguard Group Inc. manages approximately 3.9 million shares, and BlackRock Fund Advisors oversees about 3.6 million shares, based on recent reports. The significant stake held by these major investors can contribute to stock price stability and enhance market liquidity, influencing the overall Haemonetics stock ownership landscape.

Key Haemonetics Financial and Ownership Insights

Haemonetics' financial health and strategic moves are closely tied to its ownership. The company's fiscal year 2024 revenue reached $1.36 billion, with diluted earnings per share (EPS) at $3.31, underscoring its financial robustness.

• Haemonetics is a publicly traded company, meaning it is not privately held and does not have a single controlling owner.
• Institutional investors collectively hold the largest percentage of Haemonetics company ownership.
• Major institutional investors like BlackRock and Vanguard play a significant role in Haemonetics' shareholder base.
• The company's market capitalization as of July 2025 is between $3.48 billion and $3.63 billion USD.
• Recent strategic acquisitions, such as Attune Medical for $160 million in April 2024, are supported by its financial standing and ownership structure, reflecting its position within the Competitors Landscape of Haemonetics.

Haemonetics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Haemonetics Corporation is instrumental in guiding the company's strategic path and ensuring transparency for its shareholders. As of recent records, Ellen M. Zane holds the position of Chairman of the Board. The board also includes several key independent directors, such as Diane M. Bryant, Robert E. Abernathy, Michael J. Coyle, and Lloyd E. Johnson. Christopher A. Simon serves as Director, President, and Chief Executive Officer, bridging the gap between management and shareholder interests through his board presence.

Haemonetics operates under a standard one-share-one-vote system, typical for companies listed on the NYSE. This structure means that each common share generally carries a single vote. There is no public information indicating the existence of dual-class shares, special voting rights, or golden shares that would grant disproportionate control to any specific individuals or entities beyond their equity stake. The board's composition, featuring a blend of independent directors and representatives of significant shareholder interests, supports strong governance practices. While specific details regarding recent proxy contests or activist investor interventions are not readily available in recent public disclosures, the presence of institutional ownership implies that major shareholders can exert influence through their voting power and ongoing dialogue with the board and company leadership.

The voting power within Haemonetics is primarily distributed among its shareholders, with the board of directors acting as fiduciaries responsible for representing the interests of all shareholders. The company's commitment to good governance is reflected in its board's structure and the standard voting rights associated with its common stock. Understanding the Target Market of Haemonetics can provide context for how its strategic decisions, overseen by the board, aim to serve its customer base.

Haemonetics Ownership Structure

Haemonetics is a publicly traded company, meaning its ownership is distributed among its shareholders. The voting power is generally aligned with the number of shares held, reflecting a commitment to shareholder democracy.

• Publicly traded on the NYSE.
• One-share-one-vote structure.
• No disclosed dual-class shares or special voting rights.
• Board composition includes independent directors.
• Institutional investors are significant shareholders.

Haemonetics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In the last three to five years, Haemonetics Corporation has actively reshaped its ownership landscape and pursued strategic growth initiatives. A notable development was the acquisition of Attune Medical for $160 million, finalized on April 1, 2024. This move has bolstered Haemonetics' offerings, particularly within the hospital sector, which saw a significant revenue increase of 23.9% in the third quarter of fiscal year 2025, ending December 28, 2024. The company's financial management includes share repurchases and debt financing, such as the issuance of 2.5% convertible senior notes due in 2029, which provided $682.8 million in net cash, partly allocated to debt repayment. This demonstrates a proactive approach to managing its capital structure.

For fiscal year 2024, Haemonetics reported total revenue of $1.36 billion, marking a 3.95% increase from the prior year, with adjusted earnings per diluted share at $3.96. Looking ahead to fiscal year 2025, the company projects total revenue growth between 3% and 5%, with organic revenue growth anticipated at 0% to 3%. The adjusted operating margin is expected to be around 24%. Industry trends indicate a growing presence of institutional ownership in companies like Haemonetics, with large financial entities holding substantial stakes and often employing long-term investment strategies. While founder dilution is a natural outcome for a mature public company, a robust institutional investor base contributes to its stability.

The CEO of Haemonetics, Chris Simon, has highlighted the company's commitment to driving profitable growth, expanding market share through innovation, and accelerating portfolio evolution. This strategic direction is further supported by the company's ongoing financial transparency, with the announcement of Q1 fiscal year 2026 results expected on August 7, 2025, indicating continued engagement with its investors and a focus on its Growth Strategy of Haemonetics.

Institutional Investor Activity

Institutional investors are increasingly holding significant stakes in Haemonetics. These large financial organizations often adopt long-term investment strategies, contributing to the company's stability. This trend reflects confidence in Haemonetics' market position and future prospects.

Strategic Acquisitions and Financing

The acquisition of Attune Medical for $160 million in April 2024 expanded Haemonetics' hospital segment. The company also engaged in debt financing, issuing convertible senior notes to manage its capital structure and repay existing debt.

Financial Performance and Outlook

Haemonetics reported $1.36 billion in total revenue for fiscal year 2024, a 3.95% increase. Projections for fiscal year 2025 indicate continued revenue growth between 3% and 5%, with an anticipated adjusted operating margin of approximately 24%.

Leadership Vision and Investor Engagement

CEO Chris Simon emphasizes profitable growth and market share expansion through innovation. The company maintains transparency with investors, with upcoming Q1 fiscal year 2026 results scheduled for August 7, 2025.

Haemonetics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔